Table 2.
Determination of neutralizing titers of polyclonal Ig purified from sera of infected individuals and of neutralizing monoclonal IgG using HIV-1Bx08
|
Neutralizing titer, μg/mL
|
||
|---|---|---|
| iMDDCs, purified at 99% | PHA-stimulated PBMCs | |
| Polyclonal IgG | ||
| IgG no. 8 | 35 | 170 |
| IgG no. 44 | 55 | 265 |
| IgG no. 24 | 60 | 390 |
| IgG no. 11 | 165 | — |
| IgG no. 2 | 240 | — |
| IgG no. 3 | 275 | — |
| IgG control | — | — |
| Polyclonal IgA | ||
| IgA no. 8 | 210 | 190 |
| IgA no. 6 | ND | 220 |
| IgA no. 35 | — | ND |
| IgA control | — | — |
| Monoclonal IgG | ||
| 2F5 IgG1 | 2 | 40 |
| 447-52D IgG3 | 5 | 50 |
| IgG1 b12 | 2 | 50 |
| 2G12 IgG1 | 2 | > 50 |
| 4E10 IgG1 | 3 | > 50 |
Purified HIV-1Bx08 was preincubated with serial concentrations of polyclonal Ig purified from sera of HIV-1 patients or of neutralizing monoclonal IgG.
Abbreviations are explained in Table 1.